Douglas Tsao

Sell-Side Remains Optimistic On Sage Therapeutics Despite Depression Drug Disappointment

Barclays: Impax Labs-Amneal Pharma Merger Creates A Generics Leader

Barclays: Mallinckrodt's Sucampo Deal Overshadowed By Competitive Threats

Barclays: Impax Labs-Amneal Pharma Merger Creates A Generics Leader

Barclays: Mallinckrodt's Sucampo Deal Overshadowed By Competitive Threats

Barclays Injects Allergan With An Upgrade, Says Valuation Model Has Improved

Here's Why Barclays Downgraded Mallinckrodt

Barclays Injects Allergan With An Upgrade, Says Valuation Model Has Improved

Here's Why Barclays Downgraded Mallinckrodt

Teva Pharmaceuticals Hit With A Slew Of Downgrades Following Guidance Revision

In Order To Make A Turnaround, Valeant Will Need To Go Back To Basics

Douglas Tsao Recent News

Coherus Biosciences Could Be First-To-Market With A Neulasta Biosimilar

Barclays Sees 44-48% Upside In Perrigo Shares; Co. Remains Vulnerable To Activist Investors

Mylan 'Took The Sting' Out Of The EpiPen Controversy

Valeant Isn't A Short-Term Fix

Valeant Isn't A Quick Fix; Barclays Remains Positive

Valeant Just Received 2 More Downgrades

This Specialty Pharma Has Significantly Less Upside Than We Thought, Barclays Says

Barclays Cuts Charles River Labs, Sees Lack Of Demand Proof Over Long-Term

Barclays Expects M&A In Specialty Pharma To Continue, Likes Valeant And Jazz

Firms Bullish On Valeant Following Earnings, Acquisition

Zoetis Flexes Muscles; Has "Pipeline Power," Says Barclays

NuVasive (NUVA) Maintains Its Rating From Barclays